1
|
Le Guellec S, Lesluyes T, Sarot E, Valle C, Filleron T, Rochaix P, Valentin T, Pérot G, Coindre JM, Chibon F. Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas. Ann Oncol 2018; 29:1828-1835. [DOI: 10.1093/annonc/mdy194] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
|
2
|
Masson Regnault M, Ofaiche J, Boulinguez S, Tournier E, Rochaix P, Paul C, Lamant L, Meyer N. Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab. J Eur Acad Dermatol Venereol 2016; 31:e73-e74. [DOI: 10.1111/jdv.13733] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- M. Masson Regnault
- Dermatology; Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse; Toulouse France
| | - J. Ofaiche
- Dermatology; Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse; Toulouse France
| | - S. Boulinguez
- Dermatology; Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse; Toulouse France
| | - E. Tournier
- Dermatology; Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse; Toulouse France
| | - P. Rochaix
- Pathology; Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse; Toulouse France
| | - C. Paul
- Dermatology; Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse; Toulouse France
| | - L. Lamant
- Pathology; Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse; Toulouse France
- INSERM UMR 1037-CRCT; Toulouse France
| | - N. Meyer
- Dermatology; Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse; Toulouse France
- INSERM UMR 1037-CRCT; Toulouse France
| |
Collapse
|
3
|
Ducassou A, Valentin T, Filleron T, Delannes M, Ferron G, Le Guellec S, Rochaix P, Boulet B, Chevreau C. EP-1408: Adjuvant concurrent chemoradiotherapy in soft tissue sarcomas of the limbs: an effective strategy. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32658-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
4
|
Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, Traverse-Glehen A, Rousset T, Quintin-Roue I, Petrella T, Emile JF, Amara N, Rochaix P, Chenard-Neu MP, Tasei AM, Menet E, Chomarat H, Costes V, Andrac-Meyer L, Michiels JF, Chassagne-Clement C, de Leval L, Brousset P, Delsol G, Lamant L. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol 2015; 27:306-14. [PMID: 26598546 DOI: 10.1093/annonc/mdv575] [Citation(s) in RCA: 155] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Accepted: 11/11/2015] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND ALK-negative anaplastic large cell lymphoma associated with breast implant (i-ALCL) has been recently recognized as a distinct entity. Among 43 830 lymphomas registered in the French Lymphopath network since 2010, 300 breast lymphomas comprising 25 peripheral T-cell lymphomas (PTCL) were reviewed. Among PTCL, ALK-negative ALCL was the most frequent and all of them were associated with breast implants. PATIENTS AND METHODS Since 2010, all i-ALCL cases were collected from different institutions through Lymphopath. Immuno-morphologic features, molecular data and clinical outcome of 19 i-ALCLs have been retrospectively analyzed. RESULTS The median age of the patients was 61 years and the median length between breast implant and i-ALCL was 9 years. Most implants were silicone-filled and textured. Implant removal was performed in 17 out of 19 patients with additional treatment based on mostly CHOP or CHOP-like chemotherapy regimens (n = 10/19) or irradiation (n = 1/19). CHOP alone or ABVD following radiation without implant removal have been given in two patients. The two clinical presentations, i.e. effusion and less frequently tumor mass correlated with distinct histopathologic features: in situ i-ALCL (anaplastic cell proliferation confined to the fibrous capsule) and infiltrative i-ALCL (pleomorphic cells massively infiltrating adjacent tissue with eosinophils and sometimes Reed-Sternberg-like cells mimicking Hodgkin lymphoma). Malignant cells were CD30-positive, showed a variable staining for EMA and were ALK negative. Most cases had a cytotoxic T-cell immunophenotype with variable T-cell antigen loss and pSTAT3 nuclear expression. T-cell receptor genes were clonally rearranged in 13 out of 13 tested cases. After 18 months of median follow-up, the 2-year overall survival for in situ and infiltrative i-ALCL was 100% and 52.5%, respectively. CONCLUSIONS In situ i-ALCLs have an indolent clinical course and generally remain free of disease after implant removal. However, infiltrative i-ALCLs could have a more aggressive clinical course that might require additional therapy to implant removal.
Collapse
Affiliation(s)
- C Laurent
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse INSERM, U.1037, Centre de recherche en cancérologie de Toulouse-Purpan, Toulouse
| | - A Delas
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse
| | - P Gaulard
- Department of Pathology, AP-HP, Groupe hospitalier Henri Mondor-Albert Chenevier, Créteil INSERM U955, Université Paris-Est, Créteil
| | - C Haioun
- INSERM U955, Université Paris-Est, Créteil Lymphoid Malignancies Unit, AP-HP, Groupe hospitalier Henri Mondor-Albert Chenevier, Créteil
| | - A Moreau
- Department of Pathology, Centre Hospitalier Hôtel Dieu, Nantes
| | - L Xerri
- Department of Pathology, Institut Paoli-Calmettes, Marseille
| | | | - T Rousset
- Department of Pathology, Hôpital Gui de Chauliac-Saint Eloi, Montpellier
| | - I Quintin-Roue
- Department of Pathology, Centre Hospitalier de Brest, Brest, France
| | - T Petrella
- Département de Pathologie, Montréal, Canada
| | - J F Emile
- Department of Pathology, Hôpital Ambroise Paré, Boulogne
| | - N Amara
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse
| | - P Rochaix
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse
| | | | - A M Tasei
- Department of Pathology, Centre Hospitalier Henri Duffaut, Avignon
| | - E Menet
- Department of Pathology, Hôpital René Huguenin, Saint Cloud
| | | | - V Costes
- Department of Pathology, Hôpital Gui de Chauliac-Saint Eloi, Montpellier
| | | | - J F Michiels
- Department of Pathology, Centre Hospitalier Pasteur L'Archet, Nice
| | | | - L de Leval
- Pathology institut of Lausanne, Centre Hospitalier Universitaire Vaudois, Suisse, Lausanne, Switzerland
| | - P Brousset
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse INSERM, U.1037, Centre de recherche en cancérologie de Toulouse-Purpan, Toulouse
| | - G Delsol
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse INSERM, U.1037, Centre de recherche en cancérologie de Toulouse-Purpan, Toulouse
| | - L Lamant
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse INSERM, U.1037, Centre de recherche en cancérologie de Toulouse-Purpan, Toulouse
| |
Collapse
|
5
|
Modesto A, Filleron T, Chevreau C, Le Pechoux C, Rochaix P, Le Guellec S, Ducassou A, Gangloff D, Ferron G, Delannes M. Role of radiation therapy in the conservative management of sarcoma within an irradiated field. Eur J Surg Oncol 2013; 40:187-92. [PMID: 24074728 DOI: 10.1016/j.ejso.2013.07.088] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2012] [Revised: 07/16/2013] [Accepted: 07/22/2013] [Indexed: 10/26/2022] Open
Abstract
PURPOSE To report on clinical outcome and toxicity profile after combined treatment that included radiation therapy (RT) in patients with localized sarcoma within an irradiated field. PATIENTS AND METHODS Individual clinical data from all consecutive patients diagnosed and treated for a localized SIF between January 2000 and October 2011 at the Institut Claudius Regaud, Toulouse, France, were retrospectively reviewed. Outcomes of patients with SIF who underwent adjuvant or definitive radiotherapy were compared with patients who did not receive further RT. RESULTS Of the 27 patients eligible for this study: surgery alone (S), surgery followed by RT (S + RT) or definitive RT (RT) was performed in 16, 8 and 2 cases respectively. The rate of unresectable, gross or microscopically positive margin disease among the 10 re-irradiated patients was significantly higher than the non re-irradiated group (90% vs. 12% p < 0.001). After a median follow-up of 3.8 years, there was a trend toward longer survival and better local control in the subgroup of patients who received adjuvant or definitive RT compared to the rest of the cohort with an acceptable toxicity profile. The 4-year relapse free survival rates of patients treated with and without RT were 53% and 27% respectively (p = 0.09). CONCLUSION SIF complete surgical resection is often difficult to achieve, enhancing the risk of relapse. RT should be discussed in case of unresectable tumor or after suboptimal surgery as part of intensified local management that has a curative intent.
Collapse
Affiliation(s)
- A Modesto
- Institut Claudius Regaud, Department of Radiation Oncology, 20-24, rue du Pont Saint-Pierre, 31000 Toulouse, France.
| | - T Filleron
- Institut Claudius Regaud, Department of Biostatistics, 20-24, rue du Pont Saint-Pierre, 31000 Toulouse, France
| | - C Chevreau
- Institut Claudius Regaud, Department of Medical Oncology, 20-24, rue du Pont Saint-Pierre, 31000 Toulouse, France
| | - C Le Pechoux
- Institut Gustave Roussy, Department of Radiation Oncology, 114 rue Édouard-Vaillant, 94805 Villejuif, France
| | - P Rochaix
- Institut Claudius Regaud, Department of Pathology, 20-24, rue du Pont Saint-Pierre, 31000 Toulouse, France
| | - S Le Guellec
- Institut Claudius Regaud, Department of Pathology, 20-24, rue du Pont Saint-Pierre, 31000 Toulouse, France
| | - A Ducassou
- Institut Claudius Regaud, Department of Radiation Oncology, 20-24, rue du Pont Saint-Pierre, 31000 Toulouse, France
| | - D Gangloff
- Institut Claudius Regaud, Department of Surgery, 20-24, rue du Pont Saint-Pierre, 31000 Toulouse, France
| | - G Ferron
- Institut Claudius Regaud, Department of Surgery, 20-24, rue du Pont Saint-Pierre, 31000 Toulouse, France
| | - M Delannes
- Institut Claudius Regaud, Department of Radiation Oncology, 20-24, rue du Pont Saint-Pierre, 31000 Toulouse, France
| |
Collapse
|
6
|
Munsch C, Lauwers-Cances V, Gentil C, Lamant L, Rochaix P, Chevreau C, Garrido I, Lopez R, Viraben R, Paul C, Meyer N. Les facteurs pronostiques du mélanome ne permettent pas de prédire avec précision le statut histologique ganglionnaire : étude de cohorte de 612 patients. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
7
|
Garrido I, Martinet L, Filleron T, Leguellec S, Rochaix P, Girard JP. Abstract P5-04-02: Tumor Associated High Endothelial Venules (HEV) Predict Lymphocyte Infiltration and Breast Cancer Patients Clinical Outcome. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-04-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Even if lymphocyte presence within tumor tissues and its impact on cancer patient prognosis have been well documented past few years, the type of tumor vessels governing infiltration of effector cells into tumors remain to be determined. High endothelial venules (HEV) are specialized vessels for lymphocyte recruitment physiologically present in secondary lymphoidorgans also found in chronic inflammation that may impact lymphocyte recruitment and cancer patient's clinical outcome. We recently identified HEV like vessels in the peritumoral stroma of human solid tumors including melanomas, breast, colon, ovarian, and lung carcinomas. In order to better analyse the functional consequence of HEV presence within human solid tumors, we quantified HEV and tumor infiltrating lymphocytes by immunohistochemistry on serial tumor sections of 146 breast cancer patients. We demonstrate that HEV like vessels density within tumor stroma is an important predictor of CD3+, CD8+ T and B lymphocyte tumor infiltration suggesting an active role played by these vessels in peripheral blood lymphocyte migration into tumors. The breast tumor infiltrating lymphocyte phenotype associated with HEV presence was further characterized by large scale flow cytometry analysis in 30 freshly operated breast tumors. Breast tumors with a high density of HEV (HEVhi) have increased numbers of effector memory T cells (CD45RA-CD62L-) that display an activated mature phenotype (CD69+, Granzyme A+, Granzyme B+, perforin+). T cells with a naïve (CD45RA+CD62L+) and a central memory (CD45RA-CD62L+) phenotype are also specifically increased within HEVhi tumors as compared to HEVlo tumors. Finally, we analyzed the prognostic value of HEV in a retrospective cohort of 146 invasive breast cancer patients and demonstrate that HEV density within tumor stroma is an independent predictor of good clinical outcome. Indeed, HEVhi patients have a significantly longer metastasis free survival (MFS) (p< 0,004), disease free survival (DFS) (P<0,012) and overall survival (OS) (P<0,023) than HEVlo patients. HEV like vessels, through the recruitment of high number of T lymphocytes and B lymphocytes from the periphery could limit the dissemination of primary breast tumors and prevent metastatic recurrence. Therefore, signals and cells that stimulate HEV differentiation within tumor stroma represent important solid tumors therapeutic target to modulate immune infiltration and patient's clinical outcome.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-04-02.
Collapse
Affiliation(s)
- I Garrido
- Institut Claudius Regaud, Toulouse, Haute Garonne, France; CNRS, Toulouse, Haute Garonne, France
| | - L Martinet
- Institut Claudius Regaud, Toulouse, Haute Garonne, France; CNRS, Toulouse, Haute Garonne, France
| | - T Filleron
- Institut Claudius Regaud, Toulouse, Haute Garonne, France; CNRS, Toulouse, Haute Garonne, France
| | - S Leguellec
- Institut Claudius Regaud, Toulouse, Haute Garonne, France; CNRS, Toulouse, Haute Garonne, France
| | - P Rochaix
- Institut Claudius Regaud, Toulouse, Haute Garonne, France; CNRS, Toulouse, Haute Garonne, France
| | - JP. Girard
- Institut Claudius Regaud, Toulouse, Haute Garonne, France; CNRS, Toulouse, Haute Garonne, France
| |
Collapse
|
8
|
Vergez S, Delord J, Thomas F, Rochaix P, Cazelles O, Brillouet S, Filleron T, Canal P, Courbon F, Allal B. R87: Validation de la TEP-FDG dans l’évaluation précoce des inhibiteurs de l’EGFR dans les cancers épidermoïdes ORL. Bull Cancer 2010. [DOI: 10.1016/s0007-4551(15)31005-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
9
|
Teiti I, Pich C, Sarrabayrouse G, Rochaix P, Favre G, Tilkin-Mariamé B. R50: Implication des protéines Rho dans l’apoptose et la contre-attaque via Fas/FasL dans les mélanomes. Bull Cancer 2010. [DOI: 10.1016/s0007-4551(15)30967-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
10
|
Delord JP, Quideau S, Rochaix P, Caselles O, Couderc B, Hennebelle I, Courbon F, Canal P, Allal BC. Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model. Br J Cancer 2010; 103:61-72. [PMID: 20588279 PMCID: PMC2905299 DOI: 10.1038/sj.bjc.6605699] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND The incidence of ovarian cancer has been increasing worldwide and it is currently the leading cause of death from gynaecological malignancy. Unlike breast cancer, the prognostic role of the human epidermal growth factor receptor-2 (HER-2) in ovarian carcinoma remains controversial. METHODS The aim of this preclinical study was to further characterise the biological, molecular and cellular effects of trastuzumab (Herceptin) using NIH-OVCAR-3 and derived cell lines both in vitro and in vivo. RESULTS In vitro assessments have shown that trastuzumab treatment inhibited total and phosphorylated HER-2. This was associated with inhibition of the phosphorylated form of phosphatase and tensin homologue (PTEN), mitogen-activated protein kinase and AKT, and the total level of p27(kip). Inhibition of PTEN is associated with phosphorylated MEK1/2 upregulation, suggesting a specific inhibition of the protein phosphatase function of PTEN. Moreover, trastuzumab induced the upregulation of RhoB. These molecular modifications promote inhibition of cell migration and potentially restoration of tumour cell contact inhibition. RhoB induction in NIH-OVCAR-3 control cell lines mimics the molecular and cellular trastuzumab long-time exposition effects. RhoB inhibition in NIH-OVCAR-3 long-time exposed to trastuzumab cell line reverses the cellular and molecular effects observed in this model. In vivo examinations have shown that these changes are also associated with the restoration of structural, morphological and normal functions of the peritoneum of an ovarian carcinoma mouse model. CONCLUSION These results provide an indication of the mechanisms underlying the anti-tumour activity of trastuzumab that strongly implicate RhoB in an ovarian carcinoma model that does not show HER-2 amplification or overexpression. These findings highlight that trastuzumab effects involve a possible cross-talk between RhoB and PTEN in the early stages of tumour re-growth in a model of micrometastatic ovarian cancer.
Collapse
Affiliation(s)
- J-P Delord
- Laboratoire de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux (EA 3035) Université Paul Sabatier, 118 route de Narbonne, 31062 Toulouse Cedex, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Socrier Y, Lauwers-Cances V, Lamant L, Garrido I, Lauwers F, Lopez R, Rochaix P, Chevreau C, Payoux P, Viraben R, Paul C, Meyer N. Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients. Br J Dermatol 2009; 162:830-4. [DOI: 10.1111/j.1365-2133.2009.09606.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
12
|
Bellet V, Boissière F, Bibeau F, Desmetz C, Berthe ML, Rochaix P, Maudelonde T, Mangè A, Solassol J. Proteomic analysis of RCL2 paraffin-embedded tissues. J Cell Mol Med 2009; 12:2027-36. [PMID: 19012729 PMCID: PMC4506168 DOI: 10.1111/j.1582-4934.2008.00186.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Histopathological diagnosis in most of the world's hospitals is based upon formalin-fixed and paraffin-embedded (FFPE) tissues. Although this standard fixation and embedding procedure keeps the tissue in excellent form for morphological and immunohistological analysis, FFPE is inappropriate for nucleic acids and protein studies. We investigated the potential value of RCL2, a new non-toxic fixative, for sparing proteins preserved in paraffin-embedded tissues. Normal colonic mucosa tissue was fixed in RCL2 prior to paraffin embedding (RCL2P), and then processed for quality and quantity of protein conservation, as compared to frozen and FFPE tissues using complementary proteomic analysis approaches. Using 4 different protein extraction protocols, RCL2P tissue consistently showed the highest protein yield. Similar protein patterns were observed with RCL2P and frozen tissues using mono and bi-dimensional electrophoresis. Moreover, membrane, cytoplasmic and nuclear proteins, as well as phosphorylated proteins, were successfully detected using western-blot. Furthermore, protein patterns observed by mass spectrometry analysis after laser-captured microdissection were found to be identical for frozen and RCL2-fixed tissues. At last, immunohistochemistry using various antibodies showed comparable results between both tissue storage methods. We concluded that RCL2 has great potential for performing both morphological and molecular analyses on the same archival paraffin-embedded tissue sample, and can be a new method for investigating protein biomarkers.
Collapse
Affiliation(s)
- V Bellet
- CHU Montpellier, Hôpital Arnaud de Villeneuve, Department of Cellular Biology, Montpellier, France
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Delord J, Thomas F, Allal C, Delmar P, McLoughlin P, Rochaix P. Gene expression profiling on pre- and post-erlotinib tumors from HNSCC patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.17008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Balin-Gauthier D, Delord JP, Pillaire MJ, Rochaix P, Hoffman JS, Bugat R, Cazaux C, Canal P, Allal BC. Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 2008; 98:120-8. [PMID: 18182978 PMCID: PMC2359709 DOI: 10.1038/sj.bjc.6604134] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 11/12/2007] [Accepted: 11/14/2007] [Indexed: 12/24/2022] Open
Abstract
Preclinical studies have demonstrated that the chemotherapeutic action of oxaliplatin, a third generation platinum derivative, is improved when combined with cetuximab, a monoclonal antibody inhibitor of epidermal growth factor receptors. To explore the mechanism of this synergistic benefit, we used HCT-8 and HCT-116, two human colon cancer cell lines, respectively, responsive and non-responsive to the oxaliplatin/cetuximab combination. We examined the effect of drug exposure on glutathione-S-transferase-mediated oxaliplatin detoxification, DNA-platinum adducts formation, cell cycle distribution, apoptosis, and the expression of multiple targets involved in DNA replication, recombination, and repair. The major changes we found in HCT-8 were a stimulation of oxaliplatin-DNA adduct formation associated with reduced expression of the key enzyme (excision repair cross complementation group1: ERCC1) in the key repair process of oxaliplatin-DNA platinum adduct, the nucleotide excision repair (NER), both at the mRNA and protein levels. We also observed a reduced expression of factors involved in DNA replication initiation, which correlates with an enrichment of cells in the G1 phase of the cell cycle as well as an acceleration of apoptosis. None of these changes occurred in the non-responsive HCT-116 cell that we used as a negative control. These findings support the fact that cetuximab potentiates the oxaliplatin-mediated cytotoxic effect as the result of inhibition of NER and also DNA replication initiation.
Collapse
Affiliation(s)
- D Balin-Gauthier
- EA 3035 Laboratoire de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Université Paul Sabatier, Toulouse, France
| | - J-P Delord
- EA 3035 Laboratoire de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Université Paul Sabatier, Toulouse, France
- Institut Claudius Regaud, 20-24, rue du Pont Saint Pierre, Toulouse Cedex 31052, France
| | - M-J Pillaire
- équipe Instabilité génétique et cancer du département ‘Mécanismes de surveillance du génome’ Institut de Pharmacologie et de Biologie Structurale, CNRS UMR 5089 (IPBS) 205 route de Narbonne, Toulouse Cedex 31077, France
| | - P Rochaix
- EA 3035 Laboratoire de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Université Paul Sabatier, Toulouse, France
- Institut Claudius Regaud, 20-24, rue du Pont Saint Pierre, Toulouse Cedex 31052, France
| | - J-S Hoffman
- équipe Instabilité génétique et cancer du département ‘Mécanismes de surveillance du génome’ Institut de Pharmacologie et de Biologie Structurale, CNRS UMR 5089 (IPBS) 205 route de Narbonne, Toulouse Cedex 31077, France
| | - R Bugat
- EA 3035 Laboratoire de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Université Paul Sabatier, Toulouse, France
- Institut Claudius Regaud, 20-24, rue du Pont Saint Pierre, Toulouse Cedex 31052, France
| | - C Cazaux
- équipe Instabilité génétique et cancer du département ‘Mécanismes de surveillance du génome’ Institut de Pharmacologie et de Biologie Structurale, CNRS UMR 5089 (IPBS) 205 route de Narbonne, Toulouse Cedex 31077, France
| | - P Canal
- EA 3035 Laboratoire de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Université Paul Sabatier, Toulouse, France
- Institut Claudius Regaud, 20-24, rue du Pont Saint Pierre, Toulouse Cedex 31052, France
| | - B C Allal
- EA 3035 Laboratoire de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Université Paul Sabatier, Toulouse, France
- Institut Claudius Regaud, 20-24, rue du Pont Saint Pierre, Toulouse Cedex 31052, France
| |
Collapse
|
15
|
|
16
|
Benlyazid A, Thomas F, Sarini J, Rives M, Hamelin D, Courbon F, Rochaix P, Delord J. Investigation of predictive factors of response in patients with squamous-cell carcinoma of the head and neck (SCCHN) given neo-adjuvant erlotinib before surgery, updated results of a single institution experience. Radiother Oncol 2007. [DOI: 10.1016/s0167-8140(07)80095-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
17
|
Brouchet L, Rouquette I, Touriol C, Marchaix B, Rochaix P, Bigay-Game L, Hermant C, Mazieres J, Delord J, Renaud C, Didier A, Dahan M, Arnal J, Prats H. 040 Cancer bronchique rapidement évolutif : Expressions des marqueurs angiogéniques. Rev Mal Respir 2006. [DOI: 10.1016/s0761-8425(06)71868-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
18
|
Delord J, Thomas F, Benlyazid A, Sarini J, Rives M, Begue M, Courbon F, Lefebvre J, Rochaix P. Neo-adjuvant treatment with erlotinb in squamous cell carcinoma head and neck (SCCHN) patients before surgery provides an opportunity to find predictive factors of response. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.5513] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5513 Background: To date, neither immunohistochemistry (IHC) nor molecular analyses have identified prognostic markers of response to epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitors in SCCHN. Thus, the selection of patients who could benefit from such agents remains a challenge. We designed a ‘pilot’ clinical trial of patients (pts) with SCCHN pending first-line surgery of their disease. Methods: Pts with resectable SCCHN received erlotinib at 150mg/day during the period between pan-endoscopy and surgery. Pharmacokinetic (PK) samples were collected during treatment, which ceased the day before surgery. Results: Thirty five pts were recruited. All of them had resectable SCCHN: oral cavity (17 pts), oropharyngeal (7 pts), hypopharyngeal (5 pts), larygeal (6 pts). Thirty pts received full treatment with erlotinib and the main reason for discontinuation was rash. The median duration of treatment was 21 days (14–27). All pts were evaluated clinically and their tumors assessed radiologically before and after treatment. Out of 30 evaluable pts, 8 were considered as good responders (30–80% decrease in tumor size), 18 had stable disease and 2 had minor progression. Expected toxicities were observed: rash (grade 2/3 in 11 pts), diarrhea (grade 2 in 1 pt). All pts underwent surgery. The incidence of post-operative complications was similar to our historical series. No mutations in the catalytic domain of EGFR TK were found. All tumors were positive for EGFR by IHC. Correlative statistical analyses between PK, toxicity and response data are ongoing and will be presented. Neither over expression of EGFR nor other IHC markers alone were found to be good predictive markers of efficacy. Retrospective analysis of morphological and IHC evaluation in some cell cycle regulators (mainly p21) appeared to be predictive of erlotinib efficacy (sensitivity 87.5%, specificity 88%). Conclusions: Neo-adjuvant treatment with erlotinib in SCCHN pts is well-tolerated. This trial demonstrated a useful prospective method to potentially aid patient selection to improve the design of post-operative adjuvant treatment combinations. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Delord
- Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France
| | - F. Thomas
- Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France
| | - A. Benlyazid
- Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France
| | - J. Sarini
- Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France
| | - M. Rives
- Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France
| | - M. Begue
- Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France
| | - F. Courbon
- Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France
| | - J. Lefebvre
- Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France
| | - P. Rochaix
- Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France
| |
Collapse
|
19
|
Guillermet-Guibert J, Saint-Laurent N, Davenne L, Rochaix P, Cuvillier O, Culler MD, Pradayrol L, Buscail L, Susini C, Bousquet C. Novel synergistic mechanism for sst2 somatostatin and TNFα receptors to induce apoptosis: crosstalk between NF-κB and JNK pathways. Cell Death Differ 2006; 14:197-208. [PMID: 16645635 DOI: 10.1038/sj.cdd.4401939] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Somatostatin is a multifunctional hormone that modulates cell proliferation, differentiation and apoptosis. Mechanisms for somatostatin-induced apoptosis are at present mostly unsolved. Therefore, we investigated whether somatostatin receptor subtype 2 (sst2) induces apoptosis in the nontransformed murine fibroblastic NIH3T3 cells. Somatostatin receptor subtype 2 expression induced an executioner caspase-mediated apoptosis through a tyrosine phosphatase SHP-1 (Src homology domain phosphatase-1)-dependent stimulation of nuclear factor kappa B (NF-kappaB) activity and subsequent inhibition of the mitogen-activated protein kinase JNK. Tumor necrosis factor alpha (TNFalpha) stimulated both NF-kappaB and c-Jun NH2-terminal kinase (JNK) activities, which had opposite action on cell survival. Importantly, sst2 sensitized NIH3T3 cells to TNFalpha-induced apoptosis by (1) upregulating TNFalpha receptor protein expression, and sensitizing to TNFalpha-induced caspase-8 activation; (2) enhancing TNFalpha-mediated activation of NF-kappaB, resulting in JNK inhibition and subsequent executioner caspase activation and cell death. We have here unraveled a novel signaling mechanism for a G protein-coupled receptor, which directly triggers apoptosis and crosstalks with a death receptor to enhance death ligand-induced apoptosis.
Collapse
|
20
|
Delord JP, Allal C, Canal M, Mery E, Rochaix P, Hennebelle I, Pradines A, Chatelut E, Bugat R, Guichard S, Canal P. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Ann Oncol 2005; 16:1889-97. [PMID: 16219625 DOI: 10.1093/annonc/mdi405] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Although first-line chemotherapy induces complete clinical remission in many cases of epithelial ovarian cancer, relapse usually occurs 18-28 months from diagnosis owing to micrometastases. The present study aimed to evaluate the effect of trastuzumab on disease-free and overall survival in a specially designed murine model of ovarian cancer (OVCAR-3), which mimicked the natural history of human micrometastatic disease. Trastuzumab can cure the mice if started soon after induction chemotherapy. It can modestly inhibit the proliferation through mitogen-activated protein kinase signal transduction and clearly inhibit AKT phosphorylation, which is involved in survival pathway. As OVCAR-3 cell lines show no HER2 amplification or overexpression, these results warrant further studies to assess the efficacy of trastuzumab in the early stage of relapse in cancer models other than those overexpressing HER2.
Collapse
Affiliation(s)
- J P Delord
- Groupe de Pharmacologie clinique et expérimentale des médicaments anti cancéreux (EA 3035), Institut Claudius Regaud, Toulouse, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Bibeau F, Boissière F, Gourgou S, Sabourin JC, Penault-Llorca F, Rochaix P, Bralet MP, Azria D, Ychou M, Savary J. Immunohistochemical status of epidermal growth factor receptor (EGFR) in primary colorectal carcinoma and their related metastases. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Bibeau
- Ctr Val d’Aurelle, Montpellier, France; Inst Gustave Roussy, Villejuif, France; Ctr Jean Perrin, Clermont-Ferrand, France; Inst Claudius Regaud, Toulouse, France; Hôpital Paul Brousse, Villejuif, France; Merck, Lyon, France
| | - F. Boissière
- Ctr Val d’Aurelle, Montpellier, France; Inst Gustave Roussy, Villejuif, France; Ctr Jean Perrin, Clermont-Ferrand, France; Inst Claudius Regaud, Toulouse, France; Hôpital Paul Brousse, Villejuif, France; Merck, Lyon, France
| | - S. Gourgou
- Ctr Val d’Aurelle, Montpellier, France; Inst Gustave Roussy, Villejuif, France; Ctr Jean Perrin, Clermont-Ferrand, France; Inst Claudius Regaud, Toulouse, France; Hôpital Paul Brousse, Villejuif, France; Merck, Lyon, France
| | - J. C. Sabourin
- Ctr Val d’Aurelle, Montpellier, France; Inst Gustave Roussy, Villejuif, France; Ctr Jean Perrin, Clermont-Ferrand, France; Inst Claudius Regaud, Toulouse, France; Hôpital Paul Brousse, Villejuif, France; Merck, Lyon, France
| | - F. Penault-Llorca
- Ctr Val d’Aurelle, Montpellier, France; Inst Gustave Roussy, Villejuif, France; Ctr Jean Perrin, Clermont-Ferrand, France; Inst Claudius Regaud, Toulouse, France; Hôpital Paul Brousse, Villejuif, France; Merck, Lyon, France
| | - P. Rochaix
- Ctr Val d’Aurelle, Montpellier, France; Inst Gustave Roussy, Villejuif, France; Ctr Jean Perrin, Clermont-Ferrand, France; Inst Claudius Regaud, Toulouse, France; Hôpital Paul Brousse, Villejuif, France; Merck, Lyon, France
| | - M. P. Bralet
- Ctr Val d’Aurelle, Montpellier, France; Inst Gustave Roussy, Villejuif, France; Ctr Jean Perrin, Clermont-Ferrand, France; Inst Claudius Regaud, Toulouse, France; Hôpital Paul Brousse, Villejuif, France; Merck, Lyon, France
| | - D. Azria
- Ctr Val d’Aurelle, Montpellier, France; Inst Gustave Roussy, Villejuif, France; Ctr Jean Perrin, Clermont-Ferrand, France; Inst Claudius Regaud, Toulouse, France; Hôpital Paul Brousse, Villejuif, France; Merck, Lyon, France
| | - M. Ychou
- Ctr Val d’Aurelle, Montpellier, France; Inst Gustave Roussy, Villejuif, France; Ctr Jean Perrin, Clermont-Ferrand, France; Inst Claudius Regaud, Toulouse, France; Hôpital Paul Brousse, Villejuif, France; Merck, Lyon, France
| | - J. Savary
- Ctr Val d’Aurelle, Montpellier, France; Inst Gustave Roussy, Villejuif, France; Ctr Jean Perrin, Clermont-Ferrand, France; Inst Claudius Regaud, Toulouse, France; Hôpital Paul Brousse, Villejuif, France; Merck, Lyon, France
| |
Collapse
|
22
|
Sabourin JC, Cayre A, Arnould L, Bibeau F, Bralet MP, Rochaix P, Cure H, Penault-Llorca FM. Comparison of 3 commercially available immunohistochemical tests for EGFR expression in colorectal cancers. Is immunohistochemitry (IHC) reliable? J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9705] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. C. Sabourin
- Inst Gustave Roussy, Villejuif, France; Ctr J Perrin, Clermont-Ferrand, France; Ctr G-F Leclerc, Dijon, France; Ctr Val d’Aurelle, Montpellier, France; Hosp P Brousse, Villejuif, France; Inst C Regaud, Toulouse, France
| | - A. Cayre
- Inst Gustave Roussy, Villejuif, France; Ctr J Perrin, Clermont-Ferrand, France; Ctr G-F Leclerc, Dijon, France; Ctr Val d’Aurelle, Montpellier, France; Hosp P Brousse, Villejuif, France; Inst C Regaud, Toulouse, France
| | - L. Arnould
- Inst Gustave Roussy, Villejuif, France; Ctr J Perrin, Clermont-Ferrand, France; Ctr G-F Leclerc, Dijon, France; Ctr Val d’Aurelle, Montpellier, France; Hosp P Brousse, Villejuif, France; Inst C Regaud, Toulouse, France
| | - F. Bibeau
- Inst Gustave Roussy, Villejuif, France; Ctr J Perrin, Clermont-Ferrand, France; Ctr G-F Leclerc, Dijon, France; Ctr Val d’Aurelle, Montpellier, France; Hosp P Brousse, Villejuif, France; Inst C Regaud, Toulouse, France
| | - M.-P. Bralet
- Inst Gustave Roussy, Villejuif, France; Ctr J Perrin, Clermont-Ferrand, France; Ctr G-F Leclerc, Dijon, France; Ctr Val d’Aurelle, Montpellier, France; Hosp P Brousse, Villejuif, France; Inst C Regaud, Toulouse, France
| | - P. Rochaix
- Inst Gustave Roussy, Villejuif, France; Ctr J Perrin, Clermont-Ferrand, France; Ctr G-F Leclerc, Dijon, France; Ctr Val d’Aurelle, Montpellier, France; Hosp P Brousse, Villejuif, France; Inst C Regaud, Toulouse, France
| | - H. Cure
- Inst Gustave Roussy, Villejuif, France; Ctr J Perrin, Clermont-Ferrand, France; Ctr G-F Leclerc, Dijon, France; Ctr Val d’Aurelle, Montpellier, France; Hosp P Brousse, Villejuif, France; Inst C Regaud, Toulouse, France
| | - F. M. Penault-Llorca
- Inst Gustave Roussy, Villejuif, France; Ctr J Perrin, Clermont-Ferrand, France; Ctr G-F Leclerc, Dijon, France; Ctr Val d’Aurelle, Montpellier, France; Hosp P Brousse, Villejuif, France; Inst C Regaud, Toulouse, France
| |
Collapse
|
23
|
Balin D, Delord J, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P, Allal C. 378 In vivo and in vitro enhanced antitumor activity of Oxaliplatin in combination with cetuximab (C225), a chimeric monoclonal antibody anti-epidermal growth factor receptor on a panel of human colorectal tumor xenografts. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)80385-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
24
|
Delord J, Thomas F, Hennebelle I, Sarini J, Benlyazid A, Rives M, Chatelut E, Allal B, Rochaix P. 64 Assessment of antitumor effects of erlotinib prior to first-line surgical treatment of head and neck squamous cell carcinoma. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)80072-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
25
|
Regnier C, Bennet A, Malet D, Guez T, Plantavid M, Rochaix P, Monrozies X, Louvet JP, Caron P. Intraoperative testosterone assay for virilizing ovarian tumor topographic assessment: report of a Leydig cell tumor of the ovary in a premenopausal woman with an adrenal incidentaloma. J Clin Endocrinol Metab 2002; 87:3074-7. [PMID: 12107203 DOI: 10.1210/jcem.87.7.8583] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
Ovarian virilizing tumors are rare and can lead to assessment difficulties because of their small size. A 41-yr-old female was referred for evaluation of hirsutism that had increased within the previous 3 yr. Menstrual cycle length was normal. Plasma testosterone was 3.9 ng/ml (normal range, 0.2-0.8 ng/ml), was not suppressible by 2 mg dexamethasone (4.3 ng/ml), and was increased (6.3 ng/ml) after three daily injections of hCG (5000 IU). Abdominal computed tomography scan showed an adrenal nodule (13 x 6 mm) that remained unchanged after 3 months. Ultrasound examination of the pelvis was normal. Ovarian and adrenal venous catheterization did not yield additional information. Topographic assessment was made by intraoperative measurement of testosterone in the samples taken from each ovarian vein (competitive chemiluminescent immunoassay ADVIA Centaur; right ovarian vein, 105 ng/ml; left ovarian vein, 5 ng/ml; peripheral blood, 7 ng/ml). Right annexectomy resulted in normalization of testosterone levels (0.22 ng/ml). Histopathological examination found a Leydig cell tumor of hilar type (1.5 cm). This observation illustrates the usefulness of intraoperative measurement of testosterone by a rapid automated technique for topographic assessment of ovarian virilizing tumor in premenopausal women.
Collapse
Affiliation(s)
- C Regnier
- Department of Endocrinology, Centre Hospitalier Universitaire (CHU) Rangueil, avenue Jean Poulhès, 31403 Toulouse Cedex, France
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Pendaries C, Darblade B, Rochaix P, Krust A, Chambon P, Korach KS, Bayard F, Arnal JF. The AF-1 activation-function of ERalpha may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc Natl Acad Sci U S A 2002; 99:2205-10. [PMID: 11854517 PMCID: PMC122343 DOI: 10.1073/pnas.042688499] [Citation(s) in RCA: 140] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Two isoforms of estrogen receptor (ER) have been described: ERalpha and ERbeta. The initial gene targeting of ERalpha, consisting in the introduction of a Neo cassette in exon 1 [alphaERKO, hereafter called ERalpha-Neo KO (knockout)], was reported in 1993. More recently, another mouse deficient in ERalpha because of the deletion of exon 2 (ERalphaKO, hereafter called ERalpha-delta2 KO) was generated. In ovariectomized ERalpha-wild-type mice, estradiol (E(2)) increases uterine weight and basal production of endothelial nitric oxide (NO). Both of these effects are abolished in ERalpha-delta2 KO mice. In contrast, we show here that both of these effects of E(2) are partially (uterine weight) or totally (endothelial NO production) preserved in ERalpha-Neo KO. We also confirm the presence of two ERalpha mRNA splice variants in uterus and aorta from ERalpha-Neo KO mice. One of them encodes a chimeric ERalpha protein (ERalpha55), partially deleted in the A/B domain, that was detected in both uterus and aorta by Western blot analysis. The other ERalpha mRNA splice variant codes for an isoform deleted for the A/B domain (ERalpha46), which was detected in uterus of ERalpha-Neo KO, and wild-type mice. This protein isoform was not detected in aorta. The identification of these two N-terminal modified isoforms in uterus, and at least one of them in aorta, probably explains the persistence of the E(2) effects in ERalpha-Neo KO mice. Furthermore, ERalpha-Neo KO mice may help in the elucidation of the specific functions of full-length ERalpha (ERalpha66) and ERalpha46, both shown to be physiologically generated in vivo.
Collapse
MESH Headings
- Alternative Splicing
- Animals
- Aorta/metabolism
- Blotting, Western
- Dose-Response Relationship, Drug
- Endothelium, Vascular/metabolism
- Estradiol/pharmacology
- Estrogen Receptor alpha
- Exons
- Female
- Hypertrophy
- Immunohistochemistry
- Mice
- Mice, Knockout
- Models, Genetic
- Mutagenesis, Insertional
- Nitric Oxide/biosynthesis
- Organ Size
- Protein Isoforms
- Protein Structure, Tertiary
- RNA, Messenger/metabolism
- Receptors, Estrogen/genetics
- Receptors, Estrogen/physiology
- Reverse Transcriptase Polymerase Chain Reaction
- Uterus/drug effects
- Uterus/metabolism
- Uterus/pathology
Collapse
Affiliation(s)
- C Pendaries
- Institut National de la Santé et de la Recherche Médicale U397 et Laboratoire de Physiologie, Institut Louis Bugnard, Centre Hospitalier Universitaire Rangueil, 31054 Toulouse, France
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, Favre G, Couderc B. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Cancer Gene Ther 2000; 7:1543-56. [PMID: 11228533 DOI: 10.1038/sj.cgt.7700268] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The expression of costimulatory molecules such as CD70 or CD80 by gene-modified tumor cells has been shown to enhance the antitumor immune response based mainly on T lymphocytes. However, most human tumors show defects of major histocompatibility complex (MHC) expression, preventing them from being recognized by MHC-restricted T cells. To investigate if coexpression of CD70 and CD80 costimulatory molecules induces comparable antitumor responses in low and high MHC-expressing tumor cells, we used two low immunogenic murine tumor models, the B16.F10 melanoma and the TS/A mammary adenocarcinoma cell lines expressing, respectively, low and high levels of MHC class I molecules. Transfection of both CD70 and CD80 genes resulted in an increased capacity of gene-modified tumor cells to costimulate in vitro the proliferation and cytokine production of optimally activated lymphoid cells. Coexpression of CD70 and CD80 by the two tumor cell lines, TS/A and B16.F10, resulted in both cases in partial regression of subcutaneous tumors. Immunochemical analysis and studies in nude mice showed that, even in the B16.F10 model, T cells had a significant role in the antitumor response induced by combining CD70 and CD80. However, rejection of the CD70/CD80-transfected tumor cells appeared more effective in the MHC class I high TS/A model, leading to a protection against parental tumor cells. B16.F10 and TS/A transfectants were then tested with fibroblasts genetically modified to secrete interleukin-12 (IL-12) as a therapeutic vaccine in mice bearing parental tumors. In the two models tested, the injections of irradiated IL-12 and CD70/CD80 gene-modified cells generated an antitumor response to established tumors leading to the slowing down of the tumor growth rate. Although the mechanisms remain to be defined, these findings suggest that the combination of several immuno-modulatory molecules could provide additional strategies for cancer immuno-gene therapy, even for MHC expression-deficient tumors.
Collapse
MESH Headings
- Animals
- Antigens, CD
- B7-1 Antigen/biosynthesis
- CD27 Ligand
- DNA Primers
- Female
- Flow Cytometry
- Gene Expression
- Genes, MHC Class I/genetics
- Genetic Therapy/methods
- Genetic Vectors
- Humans
- Immunophenotyping
- Interferon-gamma/metabolism
- Interleukin-12/metabolism
- Mammary Neoplasms, Experimental/genetics
- Mammary Neoplasms, Experimental/metabolism
- Mammary Neoplasms, Experimental/therapy
- Melanoma, Experimental/genetics
- Melanoma, Experimental/metabolism
- Melanoma, Experimental/therapy
- Membrane Proteins/biosynthesis
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Nude
- Retroviridae/genetics
- Transfection
Collapse
Affiliation(s)
- V Douin-Echinard
- Laboratoire d'Oncologie Moléculaire et Cellulaire, Institut Claudius Regaud, Toulouse, France
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Benali N, Cordelier P, Calise D, Pages P, Rochaix P, Nagy A, Esteve JP, Pour PM, Schally AV, Vaysse N, Susini C, Buscail L. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci U S A 2000; 97:9180-5. [PMID: 10900262 PMCID: PMC16842 DOI: 10.1073/pnas.130196697] [Citation(s) in RCA: 84] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
The sst2 somatostatin receptor mediates the antiproliferative effects of somatostatin analogs. The present study demonstrates that stable expression of sst2 in the hamster pancreatic cancer cells PC-1 and PC-1.0 activates an autocrine negative loop leading to an in vitro inhibition of cell proliferation. In vivo studies conducted in Syrian golden hamsters after orthotopic implantation of PC-1.0 cells showed that both tumor growth and metastatic progression of allografts containing 100% of sst2-expressing cells were significantly inhibited for up to 20 days after implantation, as compared with control allografts that did not express sst2. A local antitumor bystander effect was observed after induction of mixed tumors containing a 1:3 ratio of sst2-expressing cells to control cells. Tumor volume and incidence of metastases of mixed tumors were significantly reduced at day 13 post implantation. This effect decreased with time as at day 20, growth of mixed tumors was similar to that of control tumors. After administration of the cytotoxic somatostatin conjugate AN-238 on day 13, antitumor bystander effect observed in mixed tumors was significantly extended to day 20. We also observed that in vitro invasiveness of sst2-expressing PC-1.0 cells was significantly reduced. Tyrosine dephosphorylation of E-cadherin may participate in restoring the E-cadherin function, reducing in turn pancreatic cancer cell motility and invasiveness. This dephosphorylation depends on the tyrosine phosphatase src homology 2-containing tyrosine phosphatase 1 (SHP-1) positively coupled to sst2 receptor. The inhibitory effect of sst2 gene expression on pancreatic cancer growth and invasion combined with chemotherapy with targeted cytotoxic somatostatin analog administration provides a rationale for a therapeutic approach to gene therapy based on in vivo sst2 gene transfer.
Collapse
Affiliation(s)
- N Benali
- Institut National de la Santé et de la Recherche Médicale U531, Institut Louis Bugnard, Institut Federatif de Recherche-31, Centre Hospitalier Universitaire Rangueil, 31403 Toulouse, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, Buscail L, Susini C. Signal transduction of somatostatin receptors negatively controlling cell proliferation. Journal of Physiology-Paris 2000; 94:205-10. [PMID: 11087998 DOI: 10.1016/s0928-4257(00)00206-0] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Somatostatin acts as an inhibitory peptide of various secretory and proliferative responses. Its effects are mediated by a family of G-protein-coupled receptors (sst1-5) that can couple to diverse signal transduction pathways such as inhibition of adenylate cyclase and guanylate cyclase, modulation of ionic conductance channels, and protein dephosphorylation. The five receptors bind the natural peptide with high affinity but only sst2, sst5 and sst3 bind the short synthetic analogues. Somatostatin negatively regulates the growth of various normal and tumour cells. This effect is mediated indirectly through inhibition of secretion of growth-promoting factors, angiogenesis and modulation of the immune system. Somatostatin can also act directly through sst receptors present on target cells. The five receptors are expressed in various normal and tumour cells, the expression of each receptor being receptor subtype and cell type specific. According to the receptor subtypes, distinct signal transduction pathways are involved in the antiproliferative action of somatostatin. Sst1, 4 and 5 modulate the MAP kinase pathway and induce G1 cell cycle arrest. Sst3 and sst2 promote apoptosis by p53-dependent and -independent mechanisms, respectively.
Collapse
Affiliation(s)
- G Ferjoux
- Inserm U 151, CHU Rangueil, IFR 31, Toulouse, France
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Chauveau N, Hamzaoui L, Rochaix P, Rigaud B, Voigt JJ, Morucci JP. Ex vivo discrimination between normal and pathological tissues in human breast surgical biopsies using bioimpedance spectroscopy. Ann N Y Acad Sci 1999; 873:42-50. [PMID: 10372148 DOI: 10.1111/j.1749-6632.1999.tb09447.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Ex vivo bioimpedance data measured on normal and cancerous female breast tissues are reported. They clearly show that the electrical properties of normal tissues, surrounding tissues, and carcinoma are different. These differences lie in the conductivity, in the characteristic frequency (frequency of the maximum of the imaginary part of the bioimpedance), and also in the shape of the Bode plots. Modeling using an R-S-Zcpe model is reported as well as indexes extracted from the real and imaginary parts of the bioimpedance. Even if a classification of the different types of tissues remains a difficult task and leads to much less precise diagnosis than microscopic examination, the electrical behavior of mammary tissue could be used to develop a noninvasive technique for early breast cancer detection.
Collapse
Affiliation(s)
- N Chauveau
- INSERM U455, CHU Purpan, Toulouse, France
| | | | | | | | | | | |
Collapse
|
31
|
Rochaix P, Delesque N, Estève JP, Saint-Laurent N, Voight JJ, Vaysse N, Susini C, Buscail L. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum Gene Ther 1999; 10:995-1008. [PMID: 10223733 DOI: 10.1089/10430349950018391] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Human pancreatic adenocarcinomas lose the ability to express sst2, the somatostatin receptor, which mediates the antiproliferative effect of somatostatin. Reintroducing sst2 into human pancreatic cancer cells by stable expression evokes an autocrine negative feedback loop leading to a constitutive activation of the sst2 gene and an inhibition of cell proliferation and tumorigenicity. In vivo studies have been conducted in athymic mice to investigate the antitumor bystander effects resulting from the transfer of the sst2 gene into human pancreatic cancer cell line BxPC-3. In mixing experiments, a local bystander effect was observed: mixed tumors containing a ratio of sst2-expressing cells to control cells of 25:75, 50:50, and 75:25 grew with a time delay of 31, 44, and 50 days, respectively, when compared with control tumors derived from control cells. Tumors containing 100% sst2-expressing cells remained quiescent for up to 80 days. A significant increase in apoptosis and a decrease in the Ki67 index were detected in mixed and sst2 tumor when compared with control tumors. In combined experiments, mice were separately xenografted with control cells on one flank and with sst2-expressing cells on the other flank. A distant antitumor effect was induced: growth of control tumors was delayed by 33 days, the Ki67 index decreased significantly, and apoptosis increased when compared with control tumors that grew alone. The distant bystander effect may be explained in part by a significant increase in serum somatostatin-like immunoreactivity levels resulting from the autocrine feedback loop produced by sst2-expressing cells and inducing an upregulation of the type 1 somatostatin receptor, sst1, which also mediates the antiproliferative effect of somatostatin. In conclusion, the local and distant antitumor bystander effects obtained in this experimental model suggest that sst2 gene transfer may represent a new therapy for pancreatic cancer.
Collapse
Affiliation(s)
- P Rochaix
- INSERM U 151, Institut Louis Bugnard, CHU Rangueil, Toulouse, France
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Lacroix-Triki M, Rochaix P, Marques B, Coindre JM, Voigt JJ. [Granular cell tumors of the skin of nonneural origin: report of 8 cases]. Ann Pathol 1999; 19:94-8. [PMID: 10349472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
We report six cases of benign fibrous histiocytoma, one case of dermatomyofibroma, one case of cutaneous leiomyosarcoma with a granular cell component. Besides the clinical, histologic and immunohistochemical features of the primary lesion, these tumors do not express S100 protein in contrast to the classic granular cell tumor described by Abrikossoff. Such a component has no implication in prognosis, which remains related to the main lesion. Ignorance of this rare event can lead to misdiagnosis, requiring a total revision of the granular cell tumor entity.
Collapse
Affiliation(s)
- M Lacroix-Triki
- Service d'Anatomie et Cytologie Pathologiques, Institut Claudius Regaud, Toulouse
| | | | | | | | | |
Collapse
|
33
|
Abstract
The expression of the pro-apoptotic proteins (Bax, Bak) and anti-apoptotic proteins (Bcl-2, Bcl-X, Mcl-1) was studied by immunohistochemistry in 110 invasive ductal breast carcinomas. The results were correlated with tumour grade, expression of oestrogen receptor (ER) and p53 protein, and the apoptotic index by combined morphology, immunohistochemistry, and a terminal UTP nick end labelling (TUNEL) procedure. Overall, Bcl-2, Bcl-X, Mcl-1, Bax, Bak, ER, and p53 were detected in 62, 75, 68, 75, 60, 68 and 26 per cent of the cases respectively, but at different levels in each case. A high apoptotic index was correlated with high tumour grade (p<0.001), overexpression of p53 (p<0.001), Bak expression (p<0.001), and low expression of Bcl-2 (p<0.001) and ER (p<0.001). No correlation was found between the apoptotic index and Bax, Bcl-X, and Mcl-1 immunostaining results. The expression of Bcl-2 and Bcl-X was correlated to that of ER. Overall, the results of this study strongly suggest that Bcl-2 and Bak expression is critical in regulating apoptosis in breast carcinomas.
Collapse
Affiliation(s)
- P Rochaix
- Laboratoire d'Anatomie et Cytologie Pathologiques, Institut Claudius Regaud, 20-24 Rue du Pont Saint Pierre, 31052 Toulouse Cedex, France
| | | | | | | | | | | |
Collapse
|
34
|
Rochaix P, Monteil-Onteniente S, Rochette-Egly C, Caratero C, Voigt JJ, Jozan S. Reduced expression of retinoic acid receptor beta protein (RAR beta) in human papillary thyroid carcinoma: immunohistochemical and western blot study. Histopathology 1998; 33:337-43. [PMID: 9822923 DOI: 10.1046/j.1365-2559.1998.00486.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
AIMS To investigate the role of retinoic acid receptor beta (RAR beta) in thyroid carcinogenesis, we have investigated its expression in human thyroid samples by combined immunohistochemistry and Western blotting. METHODS AND RESULTS Fifty-eight paraffin-embedded thyroid samples (40 normal or benign tissues, 16 papillary and two follicular carcinomas) were analysed by immunohistochemistry using a specific monoclonal antibody. Western blotting was also carried out on 11 selected samples (seven normal or benign tissues, three papillary carcinomas and one follicular carcinoma) and two human ovarian carcinomas as controls. RAR beta immunostaining was nuclear and limited to the normal epithelial thyroid tissue. A dramatic decrease in RAR beta immunostaining was observed in all the papillary carcinomas and in one follicular carcinoma. The other follicular carcinoma exhibited strong RAR beta immunostaining. By immunoblotting, a 51 kDa signal corresponding to the RAR beta was observed in nuclear extracts from normal thyroids and for one follicular carcinoma. However, this signal was lacking in the papillary carcinomas. These results were in complete agreement with the observations obtained by immunohistochemistry on the same samples. CONCLUSION We present here the first demonstration of RAR beta protein in normal human thyroid follicular cells. In addition, we found that its expression is decreased in papillary thyroid carcinoma.
Collapse
Affiliation(s)
- P Rochaix
- Service d'Anatomie et Cytologie Pathologiques, Institut Claudius Regaud, Toulouse, France
| | | | | | | | | | | |
Collapse
|
35
|
Cohen-Jonathan E, Toulas C, Rochaix P, Bachaud JM, Daly-Schveitzer N, Favre G. Preferential cytoplasmic localization of p34cdc2 in recurrent human squamous cell carcinoma after radiotherapy. Radiat Res 1997; 147:277-83. [PMID: 9052672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Duration of the G2-phase delay and arrest after exposure to ionizing radiation is thought to influence radiosensitivity. The kinase activity of the p34cdc2-cyclin B complex and the p34cdc2-cyclin A complex is implicated in G2- to M-phase transition and in G2-phase arrest after exposure to ionizing radiation. We analyzed the expression level and the subcellular location of p34cdc2, cyclin A and cyclin B in head and neck squamous cell carcinoma (SCC) tumors; samples were obtained from patients with locally nonrecurrent and recurrent tumors that had been treated by surgery and radiotherapy. No significant difference was noticed in cyclin A, cyclin B and p34cdc2 expression. However, we noted a significant preferential cytoplasmic location of p34cdc2 in recurring tumors compared to the nonrecurring ones (P < 0.001). This abnormal location of p34cdc2 occurs even in primary tumors in patients with recurring tumors, suggesting that a default in the activation of p34cdc2 kinase could be implicated in clinical radioresistance.
Collapse
Affiliation(s)
- E Cohen-Jonathan
- Department of Radiotherapy, Paul Sabatier University and INSERM U397, Toulouse, France
| | | | | | | | | | | |
Collapse
|
36
|
Rochaix P, Durroux R. [Malignant granular cell tumor. Report of a clinico-pathologic case]. Ann Pathol 1996; 16:292-5. [PMID: 9172621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The authors report a case of malignant granular cell tumor present in right buttock of a 40 year-old male. The diagnosis of these very rare (less than 50 cases reported in literature) and poor prognosis tumors is difficult. The diagnosis criteria of malignancy are reviewed regarding this clinical case and the literature.
Collapse
Affiliation(s)
- P Rochaix
- Laboratoire d'Anatomie et de Cytologie Pathologiques, Centre Cl. Régaud, Toulouse
| | | |
Collapse
|
37
|
Cohen-Jonathan E, Toulas C, Rochaix P, David J, Daly-Schveitzer N, Favre G. 820 Immunohistochemical analysis of p34cdc2 and cyclin B cell localization in recurrent head and neck squamous cell carcinoma after irradiation. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)96069-p] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
38
|
Cohen-Jonathan E, Toulas C, Rochaix P, David J, Daly-Schveitzer N, Favre G. 1042 Preferential cytoplasmic localization of P34CDC2 in recurrent head and neck squamous cell carcinoma after irradiation. Int J Radiat Oncol Biol Phys 1995. [DOI: 10.1016/0360-3016(95)97867-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Rubie H, Gladieff L, Robert A, Gaubert I, Huguet F, Rochaix P, Pein F, Michel G, Hoerni B, Sommelet D. Childhood anaplastic large cell lymphoma Ki-1/CD30: clinicopathologic features of 19 cases. Med Pediatr Oncol 1994; 22:155-61. [PMID: 8272005 DOI: 10.1002/mpo.2950220302] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The authors report their cumulative experience of 19 children with what was previously called malignant histiocytosis (MH) but is now considered a true lymphoma and termed anaplastic large cell lymphoma (ALCL). The median age at diagnosis was 10 years and 6 months (range 2 y, 11 m, to 15 y). There were 13 males and 6 females. Most cases presented with fever, wasting and enlarged, often tender, lymph nodes. Other features were: fleeting cutaneous rashes in 7 cases; spontaneous regression of lymph nodes and skin lesions were seen in 5 patients. Bone marrow involvement was present in 3 cases, pulmonary infiltrate in 5, kidneys in 2, and central nervous system in none. The morphology of lymph node involvement was consistent with so-called MH, a description originally applied to sinusoïdal infiltration by large "histiocytic" cells. The coexpression of lymphoid activation antigens Ki-1/CD 30 (18/19), epithelial membrane antigen EMA (18/19) and interleukin-2 receptor/CD 25 (10/10) was the unifying immunopathologic feature of the neoplasm. Lineage antigens were not identifiable in 8/19 instances (null phenotype), while 10/19 expressed a T-cell phenotype. None of the tumors expressed histiocytic markers. After variable, but intensive, combination chemotherapy, 15 children out of 18 evaluable achieved complete remission (CR). Among all patients, thirteen are still alive in CR (ten in first CR) with a median follow-up of 5 years. This evaluation in the pediatric age group reinforces that so-called MH is a lymphoid neoplasm, a conceptual change that could lead to improved understanding and therapy.
Collapse
MESH Headings
- Adolescent
- Antigens, Neoplasm/analysis
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Asparaginase/administration & dosage
- Child
- Child, Preschool
- Cyclophosphamide/administration & dosage
- Cytarabine/administration & dosage
- Diagnosis, Differential
- Doxorubicin/administration & dosage
- Female
- Histiocytic Sarcoma/diagnosis
- Humans
- Immunoenzyme Techniques
- Immunophenotyping
- Infant
- Ki-1 Antigen/analysis
- Lymphoma, Large-Cell, Anaplastic/diagnosis
- Lymphoma, Large-Cell, Anaplastic/drug therapy
- Lymphoma, Large-Cell, Anaplastic/pathology
- Male
- Methotrexate/administration & dosage
- Neoplasm Staging
- Prednisone/administration & dosage
- Receptors, Interleukin-2/analysis
- Remission Induction
- Retrospective Studies
- Treatment Outcome
- Vincristine/administration & dosage
Collapse
Affiliation(s)
- H Rubie
- Unit of Pediatric Hematology and Oncology, Centre Hospitalier Universitaire, Hôpital de Purpan, Toulouse, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Delisle MB, Laroche M, Dupont H, Rochaix P, Rumeau JL. Morphological analyses of paraspinal muscles: comparison of progressive lumbar kyphosis (camptocormia) and narrowing of lumbar canal by disc protrusions. Neuromuscul Disord 1993; 3:579-82. [PMID: 8186716 DOI: 10.1016/0960-8966(93)90120-9] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Progressive lumbar kyphosis (camptocormia), a rare, usually familial disease in elderly patients, is characterized by inability to immobilize the lumbar spine in relation to the pelvis. CT scan reveals selective involvement of the spinal muscles with a heterogeneous appearance and is in favour of a primary disorder of these muscles. Our aim was to define the muscular lesions and clarify their nature in this particular disorder. Biopsies of the paravertebral muscles of 14 patients with lumbar kyphosis and of 20 operated on for disc herniation or narrowed lumbar canal, were studied by light microscopy, histochemistry and electron microscopy. In both groups, type 1 fibre predominance and atrophy of type 2 fibres were observed. Ragged-red fibres with abnormal mitochondria also occurred. The differential feature was increased frequency of extensive diffuse or lobulated fibrosis in camptocormia. Other features related to pathogenesis could not be determined.
Collapse
Affiliation(s)
- M B Delisle
- Service d'Anatomie et Cytologie Pathologiques, CHU Rangueil, Toulouse, France
| | | | | | | | | |
Collapse
|
41
|
Brousset P, Rochaix P, Chittal S, Rubie H, Robert A, Delsol G. High incidence of Epstein-Barr virus detection in Hodgkin's disease and absence of detection in anaplastic large-cell lymphoma in children. Histopathology 1993; 23:189-91. [PMID: 8406393 DOI: 10.1111/j.1365-2559.1993.tb00480.x] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
By in situ hybridization with EBER oligonucleotides and immunohistochemistry with anti-latent membrane protein 1 (LMP1) antibody, we compared the detection rate of Epstein-Barr virus (EBV) in Hodgkin's disease and anaplastic large-cell lymphomas in children. Among the 13 cases of Hodgkin's disease tested, 7 (54%) were found to be EBV associated (EBER transcripts +, LMP1 +). None of the 11 cases of ALC lymphomas was found to contain EBV genomes or gene products. This may indicate that EBV is not a pathogenic agent in anaplastic large-cell lymphomas in children in comparison to Hodgkin's disease.
Collapse
Affiliation(s)
- P Brousset
- Laboratoire d'Anatomie Pathologique, Centre Hospitalier Universitaire de Purpan, Toulouse, France
| | | | | | | | | | | |
Collapse
|
42
|
Delsol G, Meggetto F, Brousset P, Cohen-Knafo E, al Saati T, Rochaix P, Gorguet B, Rubin B, Voigt JJ, Chittal S. Relation of follicular dendritic reticulum cells to Reed-Sternberg cells of Hodgkin's disease with emphasis on the expression of CD21 antigen. Am J Pathol 1993; 142:1729-38. [PMID: 7685151 PMCID: PMC1886971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Based on observations of 66 cases, in which tissues were specially processed to optimize the simultaneous preservation of cell membrane antigens and morphology, we provide evidence in favor of a relationship between follicular dendritic reticulum cells (FDRC) and Reed-Sternberg (RS) cells of Hodgkin's disease (HD) other than the lymphocyte predominance subtype. RS cells were intimately related to the FDRC network (75% of cases), and the expression of CD21 antigen was frequent (41% of cases). Exclusive expression of CD21 antigen was found in 11 cases of HD, while the expression of other B-cell-associated markers (CD19, CD20, CD22) was both variable and inconsistent. The expression of T-cell antigens (CD3, CD4, CD8) was rare. Null phenotype of RS cells was observed in 27 of 66 cases (41%). Epstein-Barr virus (EBV) nucleic acids were found in 34 of 66 (51.5%) cases. Double labeling techniques showed the presence of EBV-positive RS cells within the FDRC network. A non-B-cell origin of RS cells was supported by the differential expression of EBV latent antigens in HD (latent membrane protein+, EB nuclear antigen 2-), which is unusual in EBV-driven lymphoblastoid cell lines and EBV-positive B-cell lymphomas. FDRC and RS cells are known to share morphological traits (binucleated cells), and both cell types possess Fc receptor for IgG. The hypothesis is further backed by the findings of CD15 antigen expression by occasional RS-like dysplastic FDRC in Castleman's disease (five cases), which is characterized by hyperplasia of FDRC. Whether FDRC might be the only cells involved in the conversion to RS cells by the loss or gain of antigens remains to be determined.
Collapse
MESH Headings
- Antibodies/analysis
- Antibodies/immunology
- Antigens, CD/analysis
- Antigens, CD19
- Antigens, Differentiation, B-Lymphocyte/analysis
- Antigens, Differentiation, B-Lymphocyte/immunology
- Antigens, Differentiation, T-Lymphocyte/analysis
- Antigens, Differentiation, T-Lymphocyte/immunology
- Antigens, Viral/analysis
- Castleman Disease/immunology
- Castleman Disease/pathology
- Cell Communication/physiology
- DNA, Viral/genetics
- Dendritic Cells/immunology
- Dendritic Cells/pathology
- Dendritic Cells/physiology
- Gene Rearrangement, beta-Chain T-Cell Antigen Receptor
- Herpesvirus 4, Human/immunology
- Herpesvirus 4, Human/isolation & purification
- Herpesvirus 4, Human/physiology
- Hodgkin Disease/etiology
- Hodgkin Disease/immunology
- Hodgkin Disease/pathology
- Humans
- Immunohistochemistry
- Phenotype
- Receptors, Complement 3d/analysis
- Receptors, IgE/analysis
- Reed-Sternberg Cells/immunology
- Reed-Sternberg Cells/pathology
- Reed-Sternberg Cells/physiology
- Viral Matrix Proteins/analysis
Collapse
Affiliation(s)
- G Delsol
- Laboratoire d'Anatomie Pathologique, CHU Purpan, Toulouse, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|